Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record.

An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome

Open access
Harrison, C J, Moorman, A V, Schwab, C, Carroll, A J, Raetz, E A, Devidas, M, Strehl, S, Nebral, K, Harbott, J, Teigler-Schlegel, A, Zimmerman, M, Dastuge, N, Baruchel, A, Soulier, J, Auclerc, M-F, Attarbaschi, A, Mann, G, Stark, B, Cazzaniga, G, Chilton, L, Vandenberghe, P, Forestier, E, Haltrich, I, Raimondi, S C, Parihar, M, Bourquin, J-P, Tchinda, J, Haferlach, C, Vora, A, Hunger, S P, Heerema, N A, Haas, O A, on behalf of the Ponte di Legno International Workshop in Childhood Acute Lymphoblastic Leukemia · 2014 · Leukemia

Abstract

Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct cytogenetic subgroup of childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). To date, fluorescence in situ hybridisation (FISH), with probes specific for the RUNX1 gene, provides the only reliable detection method (five or more RUNX1 signals per cell). Patients with iAMP21 are older (median age 9 years) with a low white cell count. Previously, we demonstrated a high relapse risk when these patients were treated as standard risk. Recent studies have shown improved outcome on intensive therapy. In view of these treatment implications, accurate identification is essential. Here we have studied the cytogenetics and outcome of 530 iAMP21 patients that highlighted the association of specific secondary chromosomal and genetic changes with iAMP21 to assist in diagnosis, including the gain of chromosome X, loss or deletion of chromosome 7, ETV6 and RB1 deletions. These iAMP21 patients when treated as high risk showed the same improved outcome as those in trial-based studies regardless of the backbone chemotherapy regimen given. This study reinforces the importance of intensified treatment to reduce the risk of relapse in iAMP21 patients. This now well-defined patient subgroup should be recognised by World Health Organisation (WHO) as a distinct entity of BCP-ALL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2013.317

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 204

Metadata

Authors
Harrison, C. J., Moorman, A. V., Schwab, C., Carroll, A. J., Raetz, E. A., Devidas, M., Strehl, S., Nebral, K., Harbott, J., Teigler-Schlegel, A., Zimmerman, M., Dastuge, N., Baruchel, A., Soulier, J., Auclerc, M.-F., Attarbaschi, A., Mann, G., Stark, B., Cazzaniga, G., Chilton, L., Vandenberghe, P., Forestier, E., Haltrich, I., Raimondi, S. C., Parihar, M., Bourquin, J.-P., Tchinda, J., Haferlach, C., Vora, A., Hunger, S. P., Heerema, N. A., Haas, O. A., & Leukemia, O. B. O. T. P. D. L. I. W. I. C. A. L.
Venue
Leukemia
Published
2013-10-29
Volume
28
Issue
5
Pages
1015-1021
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2060580006
Cited by
204
References
0
FWCI
15.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. https://app.cochat.ai/papers/10.1038/leu.2013.317
The paper
Harrison, C. J., Moorman, A. V., Schwab, C., Carroll, A. J., Raetz, E. A., Devidas, M., Strehl, S., Nebral, K., Harbott, J., Teigler-Schlegel, A., Zimmerman, M., Dastuge, N., Baruchel, A., Soulier, J., Auclerc, M.-F., Attarbaschi, A., Mann, G., Stark, B., Cazzaniga, G., . . . Leukemia, O. B. O. T. P. D. L. I. W. I. C. A. L. (2014). An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. https://doi.org/10.1038/leu.2013.317

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.